GoodRx Holdings (GDRX) Cash & Equivalents (2019 - 2026)

GoodRx Holdings' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $235.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 21.69% year-over-year to $235.7 million; the TTM figure through Mar 2026 stood at $235.7 million (down 21.69% YoY), while the FY2025 annual figure was $261.8 million, down 41.6% from the prior year.
• Cash & Equivalents came in at $235.7 million for Q1 2026 at GoodRx Holdings, down from $261.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $845.4 million in Q1 2022 to a low of $235.7 million in Q1 2026.
• A 5-year average of $549.2 million and a median of $533.3 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents grew 9.07% in 2023 and slumped 46.69% in 2024, its largest moves.
• GoodRx Holdings' Cash & Equivalents stood at $757.2 million in 2022, then decreased by 11.21% to $672.3 million in 2023, then tumbled by 33.31% to $448.3 million in 2024, then slumped by 41.6% to $261.8 million in 2025, then declined by 9.97% to $235.7 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $235.7 million, $261.8 million, and $273.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison